TY - JOUR
T1 - Cerebrospinal Fluid as a Reflector of Central Cholinergic and Amino Acid Neurotransmitter Activity in Cerebellar Ataxia
AU - Manyam, Bala V.
AU - Giacobini, Ezio
AU - Ferraro, Thomas N.
AU - Hare, Theodore A.
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1990/11
Y1 - 1990/11
N2 - Cerebrospinal fluid (CSF) amino acid neurotransmitters, related compounds, and their precursors, choline levels, and acetycholinesterase activity were measured in the CSF of patients with cerebellar ataxia during a randomized, double-blind, crossover, placebo-controlled clinical trial of physostigmine salicylate. The CSF γ-aminobutyric acid, methionine, and choline levels, adjusted for age, were significantly lower in patients with cerebellar ataxia compared with controls. Physostigmine selectively reduced the level of CSF isoleucine and elevated the levels of phosphoethanolamine. No change occurred in CSF acetylcholinesterase activity and in the levels of plasma amino compounds in patients with cerebellar ataxia when compared with controls. Median ataxia scores did not statistically differ between placebo and physostigmine nor did functional improvement occur in any of the patients.
AB - Cerebrospinal fluid (CSF) amino acid neurotransmitters, related compounds, and their precursors, choline levels, and acetycholinesterase activity were measured in the CSF of patients with cerebellar ataxia during a randomized, double-blind, crossover, placebo-controlled clinical trial of physostigmine salicylate. The CSF γ-aminobutyric acid, methionine, and choline levels, adjusted for age, were significantly lower in patients with cerebellar ataxia compared with controls. Physostigmine selectively reduced the level of CSF isoleucine and elevated the levels of phosphoethanolamine. No change occurred in CSF acetylcholinesterase activity and in the levels of plasma amino compounds in patients with cerebellar ataxia when compared with controls. Median ataxia scores did not statistically differ between placebo and physostigmine nor did functional improvement occur in any of the patients.
UR - http://www.scopus.com/inward/record.url?scp=0025043716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025043716&partnerID=8YFLogxK
U2 - 10.1001/archneur.1990.00530110048016
DO - 10.1001/archneur.1990.00530110048016
M3 - Article
C2 - 1978660
AN - SCOPUS:0025043716
SN - 0003-9942
VL - 47
SP - 1194
EP - 1199
JO - Archives of Neurology
JF - Archives of Neurology
IS - 11
ER -